A multidisciplinary team of University of Miami researchers studying factors associated with health outcomes and disease risk in the Hispanic community has received a $21 million grant from the ...

The typical cost of developing new medications may not be as high as generally believed, with a few ultra-costly medications ...

A recent study published in Synthese challenges the default collection and reliance on ethno-racial data in biomedical ...

NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy. Initial data from Phase 1b/2 ex-U.S. study NEXICART-1 has demonstrated high complete response rates ...

IROS and Halia Therapeutics’ clinical trial will explore a promising new therapy for obesity, specifically designed to ...

Zoonotic diseases, also known as zoonoses, bridge the gap between animal and human health, marking a prominent area of concern for global public health.

Valley Medical Center next month will open the first phase of a new cancer facility that will increase its capacity to treat ...

Learn about clinical trials, from preclinical studies to Phase IV trials. Explore the different clinical trial phases (I-III) ...

The "AI in Clinical Trials Market by Function, Phase, Indication, Tool, End-User & Region - Global Forecast to 2030" report ...

In the world of drug development, the timing and design of clinical trials can be crucial in getting a new drug to market ...

CX-801 is under clinical development by CytomX Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate ...

CX-801 is under development for the treatment of metastatic solid tumors including metastatic melanoma, metastatic renal cell carcinoma (RCC) and head and neck squamous cell carcinoma (HNSCC). It is a ...